CompletedNCT05162170
Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study
Studying Primary mediastinal large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fondazione Italiana Linfomi - ETS
- Principal Investigator
- Ugo ConsoliU.O.C Ematologia, ARNAS Garibaldi; P.O. Garibaldi - Nesima, Catania.
- Enrollment
- 633 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2025
Study locations (30)
- U.F. Oncoematologia, IOM (Istituto Oncologico del Mediterraneo), Viagrande, Catania, Italy
- SC Ematologia, A.O. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
- Clinica di Ematologia, AOU Ospedali Riuniti, Ancona, Italy
- Azienda Ospedaliera S.Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico, Avellino, Italy
- Divisione di Oncologia e dei Tumori immuno-correlati, IRCCS Centro di Riferimento Oncologico di Aviano, Aviano, Italy
- U.O. Ematologia con Trapianto, AOU Policlinico Consorziale, Bari, Italy
- U.O.C. Ematologia - IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
- Ematologia, Ospedale "Monsignor Raffaele Dimiccoli", Barletta, Italy
- Istituto di Ematologia "Seragnoli", Policlinico S.Orsola-Malpighi, Bologna, Italy
- Ematologia, ASST Spedali Civili di Brescia, Brescia, Italy
- U.O. Ematologia e Trapianti di Midollo, Ospedale Antonio Perrino, Brindisi, Italy
- SC Ematologia e CTMO, Ospedale Businco, Cagliari, Italy
- Arnas Nuovo Ospedale Garibaldi Nesima, Catania, Italy
- Ematologia, Azienda Ospedaliero - Universitaria Policlinico - Vittorio Emanuele Presidio Ospedale Ferrarotto, Catania, Italy
- UOC Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05162170 on ClinicalTrials.govOther trials for Primary mediastinal large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE1NCT07168486CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell LymphomasUniversity of Maryland, Baltimore
- RECRUITINGPHASE2NCT06500273Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLAllogene Therapeutics
- ACTIVE NOT RECRUITINGPHASE1NCT05757700Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell LymphomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT05653271ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell MalignanciesAcepodia Biotech, Inc.
- ACTIVE NOT RECRUITINGNCT06024694Primary Mediastinal Large B-cell Lymphoma With CNS InvolvementIRCCS San Raffaele
- RECRUITINGNCT05366569Bio-CAR-T BS StudyAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
- ACTIVE NOT RECRUITINGPHASE3NCT04759586Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT04745949PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapyM.D. Anderson Cancer Center
See all trials for Primary mediastinal large B-cell lymphoma →